Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept with Pranoprofen or Omega-3 in Neovascular AMD
NCT03712670Completed
- Sponsor
- University of Brescia
- Start
- Jan 2016
- Primary completion
- Dec 2016
01
Overview
Randomised, open-label trial of pluronic in neovascular age-related macular degeneration (NVAMD), sponsored by University of Brescia. Primary endpoint: Central Retinal Thickness at 12 months. Started Jan 2016; status: completed.
02
Drugs
pluronic
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03712670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712670.